IND-enabling Studies for Platform Clinical Trials of Genome Editing in Multiple Diseases
DUE: February 22, 2024 The purpose of this NOFO is to provide support for applications for IND-enabling studies for the development of a novel in vivo genome editing therapeutic platform (genome editor plus delivery system) Read More